Lower Urine Tenofovir Concentrations Among Individuals Taking Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care Testing

Authors:

Abstract
From directly observed therapy studies, urine tenofovir (TFV) levels were 74% lower when taking tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate. Urine TFV remains quantifiable across a range of TAF adherence patterns, but a separate point-of-care lateral flow immunoassay with a lower TFV threshold will be needed to support TAF adherence monitoring.
Funding Information
  • National Institute of Mental Health
  • National Institutes of Health (K23MH122286)
  • National Institute of Allergy and Infectious Diseases (R01AI152119, R01 AI122298, R21 AI127200)
  • Gilead Sciences (CO-US-412-399)

This publication has 12 references indexed in Scilit: